Literature DB >> 21626202

Four-year follow-up of chronic neuronopathic Gaucher disease in Europeans using a modified severity scoring tool.

Elin Haf Davies1, Eugen Mengel, Anna Tylki-Szymanska, G Kleinotiene, Joerg Reinke, Ashok Vellodi.   

Abstract

In 2007, the European Task Force for neuronopathic Gaucher disease (NGD) published a review of 55 patients across four countries. Although some observations were possible, analysis was difficult due to the absence of a systematic way of assessing patients. In response to this, a Severity Scoring Tool (SST) was devised to offer a systematic means of assessing the neurological presentation seen. The SST has been modified (mSST) and is a valid tool for monitoring neurological progression. This review describes disease status and progression of neurological manifestations in a cohort of 39 chronic NGD patients across three European countries over a period of 4 years, using the mSST.

Entities:  

Mesh:

Year:  2011        PMID: 21626202     DOI: 10.1007/s10545-011-9347-z

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  6 in total

Review 1.  Management of neuronopathic Gaucher disease: a European consensus.

Authors:  A Vellodi; B Bembi; T B de Villemeur; T Collin-Histed; A Erikson; E Mengel; A Rolfs; A Tylki-Szymanska
Journal:  J Inherit Metab Dis       Date:  2001-06       Impact factor: 4.982

Review 2.  Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases.

Authors:  E H Davies; A Erikson; T Collin-Histed; E Mengel; A Tylki-Szymanska; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2007-11-12       Impact factor: 4.982

Review 3.  A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease.

Authors:  E H Davies; R Surtees; C DeVile; I Schoon; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2007-09-16       Impact factor: 4.982

4.  Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry.

Authors:  Anna Tylki-Szymańska; Ashok Vellodi; Amal El-Beshlawy; J Alexander Cole; Edwin Kolodny
Journal:  J Inherit Metab Dis       Date:  2010-01-19       Impact factor: 4.982

5.  Management of neuronopathic Gaucher disease: revised recommendations.

Authors:  A Vellodi; A Tylki-Szymanska; E H Davies; E Kolodny; B Bembi; T Collin-Histed; E Mengel; A Erikson; R Schiffmann
Journal:  J Inherit Metab Dis       Date:  2009-08-05       Impact factor: 4.982

6.  Randomized, controlled trial of miglustat in Gaucher's disease type 3.

Authors:  Raphael Schiffmann; Edmond J Fitzgibbon; Chris Harris; Catherine DeVile; Elin H Davies; Larry Abel; Ivo N van Schaik; William Benko; Margaret Timmons; Markus Ries; Ashok Vellodi
Journal:  Ann Neurol       Date:  2008-11       Impact factor: 10.422

  6 in total
  16 in total

Review 1.  Revised recommendations for the management of Gaucher disease in children.

Authors:  Paige Kaplan; Hagit Baris; Linda De Meirleir; Maja Di Rocco; Amal El-Beshlawy; Martina Huemer; Ana Maria Martins; Ioana Nascu; Marianne Rohrbach; Lynne Steinbach; Ian J Cohen
Journal:  Eur J Pediatr       Date:  2012-07-08       Impact factor: 3.183

2.  Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease.

Authors:  Aimee Donald; Cecilia Kämpe Björkvall; Ashok Vellodi; Timothy M Cox; Derralyn Hughes; Simon A Jones; Robert Wynn; Maciej Machaczka
Journal:  Orphanet J Rare Dis       Date:  2022-06-18       Impact factor: 4.303

3.  Proton MR Spectroscopy of the brain in children with neuronopathic Gaucher's disease.

Authors:  Ahmed Abdel Khalek Abdel Razek; Ahmed Abdalla; Nahed Abdel Gaber; Abeer Fathy; Ahmed Megahed; Tarek Barakat; Mona Abdel Latif Alsayed
Journal:  Eur Radiol       Date:  2013-06-20       Impact factor: 5.315

4.  Current and emerging pharmacotherapy for Gaucher disease in pediatric populations.

Authors:  Richard Sam; Emory Ryan; Emily Daykin; Ellen Sidransky
Journal:  Expert Opin Pharmacother       Date:  2021-03-25       Impact factor: 4.103

5.  Saccadic Impairments in Patients with the Norrbottnian Form of Gaucher's Disease Type 3.

Authors:  Josefine Blume; Stanislav Beniaminov; Cecilia Kämpe Björkvall; Maciej Machaczka; Per Svenningsson
Journal:  Front Neurol       Date:  2017-06-22       Impact factor: 4.003

6.  Measuring disease activity and patient experience remotely using wearable technology and a mobile phone app: outcomes from a pilot study in Gaucher disease.

Authors:  Aimee Donald; Huseyin Cizer; Niamh Finnegan; Tanya Collin-Histed; Derralynn A Hughes; Elin Haf Davies
Journal:  Orphanet J Rare Dis       Date:  2019-09-05       Impact factor: 4.123

7.  Impact of imiglucerase supply shortage on clinical and laboratory parameters in Norrbottnian patients with Gaucher disease type 3.

Authors:  Maciej Machaczka; Cecilia Kämpe Björkvall; Joanna Wieremiejczyk; Martin Paucar Arce; Kristina Myhr-Eriksson; Monika Klimkowska; Hans Hägglund; Per Svenningsson
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-09-10       Impact factor: 4.291

8.  Long-term follow-up and sudden unexpected death in Gaucher disease type 3 in Egypt.

Authors:  Magy Abdelwahab; Derek Blankenship; Raphael Schiffmann
Journal:  Neurol Genet       Date:  2016-02-25

9.  CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease.

Authors:  John Marshall; Ying Sun; Dinesh S Bangari; Eva Budman; Hyejung Park; Jennifer B Nietupski; Amy Allaire; Mary A Cromwell; Bing Wang; Gregory A Grabowski; John P Leonard; Seng H Cheng
Journal:  Mol Ther       Date:  2016-03-07       Impact factor: 11.454

10.  Oculomotor and Vestibular Findings in Gaucher Disease Type 3 and Their Correlation with Neurological Findings.

Authors:  Tatiana Bremova-Ertl; Raphael Schiffmann; Marc C Patterson; Nadia Belmatoug; Thierry Billette de Villemeur; Stanislavs Bardins; Claudia Frenzel; Věra Malinová; Silvia Naumann; Juliane Arndt; Eugen Mengel; Jörg Reinke; Ralf Strobl; Michael Strupp
Journal:  Front Neurol       Date:  2018-01-15       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.